Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fulvestrant + Abemaciclib in HR+ Endometrial Adenocarcinoma
NCT03643510Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Aug 2018
- Primary completion
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of abemaciclib, fulvestrant in endometrial adenocarcinoma, sponsored by Memorial Sloan Kettering Cancer Center. Started Aug 2018; status: completed.
02
Drugs
abemaciclibfulvestrant
03
Conditions
endometrial adenocarcinoma
Beyond the preview
Go deeper on NCT03643510.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03643510.